How Melanoma Is Identified, Staged and Managed in Clinical Care

Melanoma is a type of skin cancer that begins in melanocytes, the pigment-producing cells found mainly in the skin but also in the eyes and a few other tissues. It is less common than some other skin cancers, but it is more likely to spread to other parts of the body if not caught early, which is why it receives close clinical attention. Learning how melanoma is recognized, assessed and treated is a core part of dermatology, oncology and primary care. Readers who want to study the subject in a structured way can look at the course Micro Diploma: Melanoma Management, which covers the topic in a focused format.

Diagnosis usually begins with a visual examination of a suspicious lesion. Clinicians often use the ABCDE framework, which looks at asymmetry, border irregularity, color variation, diameter and evolution over time. Any lesion that raises concern is normally removed and sent for histopathology, the microscopic examination that confirms whether cells are cancerous and provides details such as thickness and the presence of ulceration.

Once melanoma is confirmed, staging determines how far the disease has progressed. The Breslow thickness, measured in millimeters from the top of the skin to the deepest point of invasion, is a central factor in the primary staging system. Clinicians also assess whether the cancer has reached nearby lymph nodes or distant organs, since these findings strongly influence prognosis and treatment choices.

In a typical clinical pathway, a thin melanoma is managed with wide local excision, which removes the tumor along with a margin of normal tissue. For thicker or higher-risk tumors, clinicians may recommend sentinel lymph node biopsy to check whether cancer cells have spread to the regional lymph nodes. In an education or training setting, trainees often practice these steps by reviewing anonymized case reports, comparing how different tumor thicknesses lead to different surgical and follow-up plans.

For advanced disease, management has changed considerably over the past several decades. Targeted therapies that act on specific gene mutations, such as BRAF, and immunotherapies that help the immune system recognize and attack tumor cells are now used in many patients with metastatic melanoma. Treatment teams usually include surgeons, medical oncologists, radiation specialists, pathologists and nurses, who coordinate decisions about each patient's care and follow-up schedule.

Melanoma management is not without limitations. Immunotherapies can produce serious side effects that affect the skin, gut, liver and other organs, and not every patient responds to them. Researchers continue to debate the best criteria for selecting patients for sentinel node biopsy and adjuvant therapy, as well as how to balance the benefits of intensive surveillance against its costs and the anxiety it can cause. Access to specialist care also varies widely between regions, which affects how consistently best practices are applied.

The main takeaway is that early detection and accurate staging remain the foundation of effective melanoma care, while treatment options continue to expand. Future development is likely to focus on better biomarkers that predict who will benefit from specific therapies, and on tools that help clinicians and patients make informed decisions together.